 Elizabeth Kessler
Concepts (201)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 13 | 2023 | 925 | 2.640 |
Why?
| | Urinary Bladder Neoplasms | 7 | 2022 | 196 | 2.480 |
Why?
| | Carcinoma, Renal Cell | 8 | 2023 | 173 | 2.160 |
Why?
| | Kidney Neoplasms | 10 | 2023 | 333 | 2.140 |
Why?
| | Suicide, Assisted | 5 | 2023 | 20 | 1.670 |
Why?
| | Prostate-Specific Antigen | 3 | 2021 | 153 | 1.390 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 5 | 2022 | 1361 | 0.970 |
Why?
| | Physicians | 5 | 2023 | 772 | 0.960 |
Why?
| | Antineoplastic Agents | 9 | 2021 | 1895 | 0.910 |
Why?
| | Oncologists | 1 | 2022 | 31 | 0.770 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2018 | 863 | 0.760 |
Why?
| | Orchiectomy | 3 | 2016 | 57 | 0.680 |
Why?
| | Euterpe | 1 | 2018 | 6 | 0.630 |
Why?
| | Aged | 23 | 2023 | 19094 | 0.580 |
Why?
| | Prostatic Neoplasms, Castration-Resistant | 2 | 2017 | 41 | 0.570 |
Why?
| | Abiraterone Acetate | 1 | 2017 | 15 | 0.570 |
Why?
| | Plant Extracts | 1 | 2018 | 155 | 0.550 |
Why?
| | Frailty | 1 | 2018 | 114 | 0.530 |
Why?
| | Prednisone | 1 | 2017 | 231 | 0.530 |
Why?
| | Indazoles | 2 | 2014 | 58 | 0.520 |
Why?
| | Biliary Tract Neoplasms | 1 | 2015 | 20 | 0.520 |
Why?
| | Capecitabine | 1 | 2015 | 45 | 0.520 |
Why?
| | Imidazoles | 2 | 2014 | 211 | 0.490 |
Why?
| | Deoxycytidine | 1 | 2015 | 138 | 0.490 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2015 | 52 | 0.480 |
Why?
| | Carcinoma, Papillary | 1 | 2015 | 73 | 0.480 |
Why?
| | Spinal Neoplasms | 1 | 2014 | 28 | 0.470 |
Why?
| | Piperidines | 1 | 2015 | 161 | 0.470 |
Why?
| | Anilides | 4 | 2022 | 67 | 0.460 |
Why?
| | Neoplasms | 5 | 2023 | 2105 | 0.460 |
Why?
| | Immunotherapy | 1 | 2018 | 475 | 0.460 |
Why?
| | Quinazolines | 1 | 2015 | 243 | 0.460 |
Why?
| | Neoplasm Metastasis | 5 | 2020 | 528 | 0.460 |
Why?
| | Testicular Neoplasms | 3 | 2023 | 97 | 0.450 |
Why?
| | Humans | 48 | 2023 | 114756 | 0.430 |
Why?
| | Canada | 5 | 2023 | 322 | 0.390 |
Why?
| | Aged, 80 and over | 7 | 2021 | 6350 | 0.370 |
Why?
| | Geriatric Assessment | 4 | 2021 | 176 | 0.370 |
Why?
| | Pyridines | 4 | 2022 | 425 | 0.370 |
Why?
| | Protein Kinase Inhibitors | 2 | 2017 | 795 | 0.370 |
Why?
| | Male | 27 | 2023 | 55579 | 0.360 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2015 | 584 | 0.350 |
Why?
| | Adaptation, Psychological | 1 | 2014 | 547 | 0.340 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 2 | 2023 | 62 | 0.340 |
Why?
| | Aging | 2 | 2018 | 1620 | 0.330 |
Why?
| | Caregivers | 2 | 2023 | 717 | 0.330 |
Why?
| | Pancreatic Neoplasms | 1 | 2015 | 732 | 0.320 |
Why?
| | Androgen Antagonists | 3 | 2020 | 70 | 0.310 |
Why?
| | Neoadjuvant Therapy | 2 | 2021 | 305 | 0.310 |
Why?
| | Neoplasm Staging | 5 | 2023 | 1176 | 0.300 |
Why?
| | Urothelium | 3 | 2019 | 33 | 0.280 |
Why?
| | Stress, Psychological | 1 | 2014 | 944 | 0.270 |
Why?
| | Neoplasm Invasiveness | 2 | 2020 | 445 | 0.270 |
Why?
| | Treatment Outcome | 7 | 2019 | 9089 | 0.270 |
Why?
| | Carcinoma, Transitional Cell | 2 | 2019 | 53 | 0.270 |
Why?
| | Middle Aged | 13 | 2023 | 26757 | 0.230 |
Why?
| | Surveys and Questionnaires | 7 | 2023 | 4625 | 0.230 |
Why?
| | Quality of Life | 4 | 2022 | 2358 | 0.220 |
Why?
| | Penile Neoplasms | 1 | 2023 | 7 | 0.220 |
Why?
| | Terminally Ill | 1 | 2023 | 33 | 0.210 |
Why?
| | Bone Neoplasms | 2 | 2015 | 194 | 0.210 |
Why?
| | Molecular Targeted Therapy | 2 | 2018 | 347 | 0.210 |
Why?
| | Female | 15 | 2023 | 59507 | 0.200 |
Why?
| | Lung Neoplasms | 1 | 2014 | 2199 | 0.200 |
Why?
| | Adenosine Deaminase | 1 | 2021 | 24 | 0.200 |
Why?
| | Pilot Projects | 4 | 2023 | 1370 | 0.190 |
Why?
| | Vasculitis | 1 | 2021 | 70 | 0.190 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2023 | 152 | 0.190 |
Why?
| | Ureteral Neoplasms | 1 | 2019 | 1 | 0.170 |
Why?
| | Nephroureterectomy | 1 | 2019 | 2 | 0.170 |
Why?
| | Biopsy | 2 | 2021 | 1040 | 0.170 |
Why?
| | Medical Oncology | 1 | 2021 | 229 | 0.170 |
Why?
| | Hospice Care | 1 | 2022 | 185 | 0.170 |
Why?
| | Fruit and Vegetable Juices | 1 | 2018 | 12 | 0.160 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2023 | 664 | 0.160 |
Why?
| | Pregnancy Complications, Neoplastic | 1 | 2018 | 51 | 0.150 |
Why?
| | Cancer Survivors | 1 | 2022 | 206 | 0.150 |
Why?
| | Prognosis | 4 | 2023 | 3334 | 0.150 |
Why?
| | Mass Screening | 2 | 2021 | 1003 | 0.150 |
Why?
| | Wilms Tumor | 1 | 2018 | 69 | 0.150 |
Why?
| | Frail Elderly | 1 | 2018 | 105 | 0.150 |
Why?
| | Checklist | 1 | 2018 | 83 | 0.140 |
Why?
| | Proton Therapy | 1 | 2017 | 10 | 0.140 |
Why?
| | Seminoma | 1 | 2017 | 17 | 0.140 |
Why?
| | Age Factors | 3 | 2018 | 2890 | 0.140 |
Why?
| | Taxoids | 1 | 2017 | 94 | 0.140 |
Why?
| | Cisplatin | 1 | 2018 | 263 | 0.140 |
Why?
| | Colorado | 2 | 2023 | 4086 | 0.140 |
Why?
| | Documentation | 1 | 2018 | 167 | 0.130 |
Why?
| | Nutritional Status | 1 | 2018 | 286 | 0.130 |
Why?
| | Communication | 1 | 2022 | 747 | 0.130 |
Why?
| | Palliative Care | 2 | 2022 | 641 | 0.130 |
Why?
| | Clinical Decision-Making | 1 | 2018 | 268 | 0.130 |
Why?
| | Adult | 9 | 2023 | 30548 | 0.130 |
Why?
| | Decision Making | 1 | 2022 | 781 | 0.120 |
Why?
| | Receptor Protein-Tyrosine Kinases | 2 | 2021 | 227 | 0.120 |
Why?
| | Attitude of Health Personnel | 2 | 2022 | 977 | 0.120 |
Why?
| | Patient Acceptance of Health Care | 1 | 2020 | 680 | 0.120 |
Why?
| | Patient Selection | 1 | 2018 | 641 | 0.120 |
Why?
| | Radiation Tolerance | 1 | 2015 | 92 | 0.120 |
Why?
| | Clinical Trials, Phase I as Topic | 1 | 2014 | 46 | 0.120 |
Why?
| | Muscle, Smooth | 1 | 2015 | 144 | 0.120 |
Why?
| | Feasibility Studies | 3 | 2023 | 737 | 0.110 |
Why?
| | Risk Assessment | 2 | 2023 | 2973 | 0.110 |
Why?
| | Neoplasms, Complex and Mixed | 1 | 2013 | 7 | 0.110 |
Why?
| | Carcinoma, Medullary | 1 | 2013 | 13 | 0.110 |
Why?
| | Demography | 1 | 2014 | 262 | 0.110 |
Why?
| | Lymphatic Metastasis | 1 | 2014 | 280 | 0.110 |
Why?
| | Energy Metabolism | 1 | 2018 | 729 | 0.110 |
Why?
| | Angiogenesis Inhibitors | 1 | 2014 | 215 | 0.100 |
Why?
| | Health Personnel | 1 | 2018 | 574 | 0.100 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2013 | 229 | 0.100 |
Why?
| | Needs Assessment | 1 | 2014 | 313 | 0.100 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2014 | 482 | 0.100 |
Why?
| | Radiosurgery | 1 | 2015 | 302 | 0.100 |
Why?
| | Bone Diseases | 1 | 2012 | 57 | 0.100 |
Why?
| | Radiography | 1 | 2014 | 811 | 0.100 |
Why?
| | Sarcoma | 1 | 2013 | 138 | 0.100 |
Why?
| | Antibodies, Monoclonal | 1 | 2018 | 1270 | 0.100 |
Why?
| | Disease Progression | 1 | 2018 | 2387 | 0.100 |
Why?
| | Drugs, Investigational | 1 | 2011 | 30 | 0.100 |
Why?
| | Urinary Bladder | 1 | 2013 | 164 | 0.100 |
Why?
| | Pyrimidines | 1 | 2014 | 378 | 0.100 |
Why?
| | Gonadotropin-Releasing Hormone | 1 | 2012 | 188 | 0.090 |
Why?
| | Sulfonamides | 1 | 2014 | 445 | 0.090 |
Why?
| | Quality Improvement | 1 | 2018 | 951 | 0.090 |
Why?
| | Practice Guidelines as Topic | 1 | 2018 | 1393 | 0.090 |
Why?
| | B7-H1 Antigen | 2 | 2022 | 142 | 0.090 |
Why?
| | Neoplasm Proteins | 1 | 2013 | 385 | 0.090 |
Why?
| | Recombinant Fusion Proteins | 1 | 2012 | 617 | 0.090 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2013 | 447 | 0.080 |
Why?
| | Survival Rate | 3 | 2019 | 1642 | 0.080 |
Why?
| | United States | 4 | 2023 | 12176 | 0.080 |
Why?
| | Survival Analysis | 2 | 2021 | 1218 | 0.070 |
Why?
| | Cohort Studies | 1 | 2015 | 4901 | 0.070 |
Why?
| | Risk Factors | 1 | 2018 | 8627 | 0.060 |
Why?
| | Nephrectomy | 2 | 2018 | 149 | 0.060 |
Why?
| | Retrospective Studies | 4 | 2023 | 12515 | 0.060 |
Why?
| | Cross-Sectional Studies | 1 | 2014 | 4409 | 0.060 |
Why?
| | Drug Interactions | 2 | 2017 | 340 | 0.050 |
Why?
| | Morals | 1 | 2023 | 65 | 0.050 |
Why?
| | Disclosure | 1 | 2023 | 101 | 0.050 |
Why?
| | Telephone | 1 | 2023 | 152 | 0.050 |
Why?
| | SEER Program | 1 | 2023 | 196 | 0.050 |
Why?
| | Severe Combined Immunodeficiency | 1 | 2021 | 19 | 0.050 |
Why?
| | Agammaglobulinemia | 1 | 2021 | 30 | 0.050 |
Why?
| | Intention to Treat Analysis | 1 | 2021 | 68 | 0.050 |
Why?
| | Follow-Up Studies | 2 | 2022 | 4420 | 0.050 |
Why?
| | Prostate | 1 | 2022 | 156 | 0.050 |
Why?
| | Clinical Trials as Topic | 2 | 2016 | 935 | 0.040 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2021 | 350 | 0.040 |
Why?
| | Hospitals | 1 | 2023 | 580 | 0.040 |
Why?
| | Neoplasm Grading | 1 | 2019 | 242 | 0.040 |
Why?
| | Survivors | 1 | 2022 | 411 | 0.040 |
Why?
| | Central Nervous System | 1 | 2020 | 237 | 0.040 |
Why?
| | Young Adult | 3 | 2018 | 10463 | 0.040 |
Why?
| | Disease-Free Survival | 1 | 2019 | 623 | 0.040 |
Why?
| | Proportional Hazards Models | 1 | 2021 | 1080 | 0.040 |
Why?
| | Drug Administration Schedule | 1 | 2019 | 718 | 0.040 |
Why?
| | National Cancer Institute (U.S.) | 1 | 2017 | 40 | 0.040 |
Why?
| | Pregnancy Outcome | 1 | 2018 | 337 | 0.030 |
Why?
| | Endothelial Cells | 1 | 2021 | 681 | 0.030 |
Why?
| | Cognition | 1 | 2023 | 989 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 2 | 2018 | 3039 | 0.030 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 1 | 2015 | 119 | 0.030 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2015 | 125 | 0.030 |
Why?
| | Cytokines | 1 | 2021 | 1843 | 0.030 |
Why?
| | beta-Galactosidase | 1 | 2013 | 62 | 0.030 |
Why?
| | Breeding | 1 | 2013 | 55 | 0.030 |
Why?
| | Staining and Labeling | 1 | 2013 | 134 | 0.030 |
Why?
| | Hyperplasia | 1 | 2013 | 163 | 0.030 |
Why?
| | Keratins | 1 | 2013 | 176 | 0.030 |
Why?
| | Tumor Stem Cell Assay | 1 | 2012 | 33 | 0.030 |
Why?
| | Organ Specificity | 1 | 2013 | 268 | 0.030 |
Why?
| | Adenoviridae | 1 | 2013 | 185 | 0.030 |
Why?
| | Integrases | 1 | 2013 | 116 | 0.030 |
Why?
| | Fluorescent Antibody Technique | 1 | 2013 | 396 | 0.030 |
Why?
| | Animals | 4 | 2017 | 31761 | 0.030 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2013 | 333 | 0.030 |
Why?
| | RNA, Untranslated | 1 | 2013 | 113 | 0.020 |
Why?
| | Databases, Factual | 1 | 2017 | 1128 | 0.020 |
Why?
| | Mutation | 1 | 2021 | 3350 | 0.020 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2012 | 706 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2018 | 2269 | 0.020 |
Why?
| | ErbB Receptors | 1 | 2012 | 560 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2013 | 1635 | 0.020 |
Why?
| | Adolescent | 2 | 2017 | 17808 | 0.020 |
Why?
| | Time Factors | 1 | 2019 | 6124 | 0.020 |
Why?
| | Practice Patterns, Physicians' | 1 | 2017 | 1178 | 0.020 |
Why?
| | Genotype | 1 | 2013 | 1774 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2012 | 1846 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2013 | 1951 | 0.020 |
Why?
| | Prospective Studies | 1 | 2019 | 6217 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2018 | 5035 | 0.020 |
Why?
| | Biomarkers, Tumor | 1 | 2013 | 1053 | 0.020 |
Why?
| | Pregnancy | 1 | 2018 | 5525 | 0.020 |
Why?
| | Mice | 2 | 2013 | 14916 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2013 | 2763 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2012 | 2725 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2012 | 2196 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2012 | 3542 | 0.010 |
Why?
|
|
Kessler's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|